Smithfield Trust Co Sells 214 Shares of CVS Health Co. (NYSE:CVS)

Smithfield Trust Co reduced its position in CVS Health Co. (NYSE:CVS) by 4.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,190 shares of the pharmacy operator’s stock after selling 214 shares during the period. Smithfield Trust Co’s holdings in CVS Health were worth $232,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. PDS Planning Inc acquired a new position in shares of CVS Health during the third quarter worth $243,000. United Advisor Group LLC acquired a new stake in CVS Health in the third quarter worth about $206,000. M&G PLC boosted its holdings in CVS Health by 2.1% in the third quarter. M&G PLC now owns 909,675 shares of the pharmacy operator’s stock worth $57,310,000 after acquiring an additional 18,955 shares in the last quarter. Poplar Forest Capital LLC boosted its holdings in CVS Health by 27.1% in the third quarter. Poplar Forest Capital LLC now owns 486,074 shares of the pharmacy operator’s stock worth $30,564,000 after acquiring an additional 103,602 shares in the last quarter. Finally, WoodTrust Financial Corp acquired a new stake in CVS Health in the third quarter worth about $231,000. 80.66% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.24% of the stock is currently owned by company insiders.

CVS Health Stock Performance

Shares of CVS stock opened at $66.01 on Thursday. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $80.75. The business’s 50 day moving average is $55.58 and its two-hundred day moving average is $56.63. The company has a market capitalization of $83.23 billion, a P/E ratio of 18.04, a P/E/G ratio of 0.98 and a beta of 0.61.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Analysts expect that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 4.03%. The ex-dividend date was Thursday, January 23rd. CVS Health’s dividend payout ratio is presently 72.68%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent analyst reports. Royal Bank of Canada cut their price target on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Wolfe Research upped their price target on shares of CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Piper Sandler lowered their price target on CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research report on Monday, November 25th. Leerink Partnrs raised CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. increased their price target on shares of CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a report on Tuesday, February 18th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $69.83.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.